NZS Capital LLC Buys 1,652 Shares of Axon Enterprise, Inc $AXON

NZS Capital LLC grew its position in Axon Enterprise, Inc (NASDAQ:AXON) by 6.2% in the 3rd quarter, Holdings Channel reports. The institutional investor owned 28,375 shares of the biotechnology company’s stock after purchasing an additional 1,652 shares during the period. NZS Capital LLC’s holdings in Axon Enterprise were worth $20,363,000 at the end of the most recent quarter.

Other hedge funds have also added to or reduced their stakes in the company. Vanguard Group Inc. grew its position in shares of Axon Enterprise by 4.2% during the 3rd quarter. Vanguard Group Inc. now owns 9,314,164 shares of the biotechnology company’s stock worth $6,684,217,000 after buying an additional 376,904 shares during the period. Geode Capital Management LLC increased its position in shares of Axon Enterprise by 5.9% in the second quarter. Geode Capital Management LLC now owns 2,072,186 shares of the biotechnology company’s stock valued at $1,713,332,000 after acquiring an additional 115,349 shares during the last quarter. Jennison Associates LLC boosted its holdings in shares of Axon Enterprise by 53.8% in the 3rd quarter. Jennison Associates LLC now owns 943,944 shares of the biotechnology company’s stock valued at $677,412,000 after buying an additional 330,213 shares during the last quarter. Vestor Capital LLC grew its position in shares of Axon Enterprise by 438,636.3% in the 2nd quarter. Vestor Capital LLC now owns 833,599 shares of the biotechnology company’s stock valued at $690,170,000 after acquiring an additional 833,409 shares during the period. Finally, Norges Bank acquired a new position in Axon Enterprise during the second quarter worth approximately $637,806,000. Institutional investors own 79.08% of the company’s stock.

More Axon Enterprise News

Here are the key news stories impacting Axon Enterprise this week:

• Positive Sentiment: TD Cowen and other analysts boosted Axon’s outlook after strong bookings and continued growth in subscription/ARR, leading to an upward revision in price targets that supports the bull case. Price Target Raised After Strong Bookings Growth
• Positive Sentiment: Geopolitical headlines lifted defense-related names, including Axon, as investors favored companies exposed to public-safety and defense spending, providing near-term demand for the stock. Northrop Grumman, Axon and RTX lifted most as defense stocks gain on Iran war
• Neutral Sentiment: Axon presented at the Morgan Stanley TMT conference — management exposure at investor conferences increases visibility and can drive re-rating if they provide positive guidance, but the transcript contains no immediate market-moving surprise. Conference Presentation Transcript
• Neutral Sentiment: Recent data on short interest in the reporting snippets is anomalous/zeroed (NaN/0) and not informative — there’s no clear short squeeze signal from that data as published.
• Neutral Sentiment: Post-earnings coverage highlights a strong growth story (Axon 911, ARR growth) but also flags a very high forward earnings multiple, implying the stock needs near-perfect execution to justify the premium. This keeps sentiment mixed. Analysts: Axon can gain another 30%
• Negative Sentiment: An insider (Isaiah Fields) sold 2,000 shares at roughly $535, trimming his position by ~3.5%; insider selling can be perceived negatively even if modest in size. SEC Filing — Form 4
• Negative Sentiment: Coverage aggregated by TipRanks and others notes multiple insider sales across the company, which can weigh on sentiment if investors interpret the moves as insiders taking chips off the table. Top Axon Insiders Quietly Cash In

Insider Buying and Selling at Axon Enterprise

In other Axon Enterprise news, CAO Jennifer H. Mak sold 1,134 shares of the company’s stock in a transaction on Friday, December 19th. The stock was sold at an average price of $600.00, for a total value of $680,400.00. Following the completion of the transaction, the chief accounting officer owned 13,740 shares in the company, valued at $8,244,000. This represents a 7.62% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, insider Isaiah Fields sold 2,000 shares of the business’s stock in a transaction dated Friday, February 27th. The stock was sold at an average price of $535.01, for a total transaction of $1,070,020.00. Following the completion of the transaction, the insider directly owned 55,588 shares in the company, valued at $29,740,135.88. This trade represents a 3.47% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders sold a total of 56,128 shares of company stock valued at $31,220,883 in the last ninety days. 5.70% of the stock is owned by corporate insiders.

Axon Enterprise Stock Performance

NASDAQ AXON opened at $579.09 on Wednesday. Axon Enterprise, Inc has a 1 year low of $396.41 and a 1 year high of $885.91. The company has a debt-to-equity ratio of 0.53, a current ratio of 2.53 and a quick ratio of 2.29. The firm has a market cap of $46.56 billion, a price-to-earnings ratio of 380.98, a PEG ratio of 12.21 and a beta of 1.46. The company has a fifty day moving average price of $537.12 and a 200-day moving average price of $621.06.

Axon Enterprise (NASDAQ:AXON) last issued its quarterly earnings data on Tuesday, February 24th. The biotechnology company reported $2.15 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.60 by $0.55. The business had revenue of $796.72 million during the quarter, compared to the consensus estimate of $755.29 million. Axon Enterprise had a net margin of 4.48% and a return on equity of 2.82%. The firm’s quarterly revenue was up 38.5% compared to the same quarter last year. During the same period in the prior year, the firm posted $2.08 EPS. As a group, equities research analysts predict that Axon Enterprise, Inc will post 5.8 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

A number of equities analysts have recently weighed in on the company. Robert W. Baird set a $800.00 target price on Axon Enterprise in a research note on Wednesday, February 25th. Piper Sandler reduced their price target on shares of Axon Enterprise from $753.00 to $690.00 and set an “overweight” rating on the stock in a research report on Wednesday, February 25th. Needham & Company LLC lowered their target price on Axon Enterprise from $870.00 to $600.00 and set a “buy” rating for the company in a research note on Friday, February 20th. Barclays cut their price objective on Axon Enterprise from $702.00 to $682.00 and set an “overweight” rating on the stock in a report on Wednesday, February 25th. Finally, Craig Hallum restated a “buy” rating and issued a $820.00 price target on shares of Axon Enterprise in a research report on Wednesday, February 25th. Sixteen investment analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the company’s stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $762.93.

About Axon Enterprise

Axon Enterprise, Inc develops technology and weapons systems for public safety and law enforcement agencies, combining hardware, software and cloud services. The company’s hardware portfolio includes conducted energy weapons (commonly known as TASER devices), body-worn cameras and in-car camera systems. Axon pairs these devices with a suite of connected products and accessories designed to capture, store and manage field evidence.

Beyond hardware, Axon operates a subscription-based software platform for digital evidence management, evidence review and records management.